Targeting abnormal ER stress responses in tumors: A new approach to cancer immunotherapy.
Academic Article
Overview
abstract
Cancers thrive under adverse conditions and simultaneously inhibit antitumor immunity. We recently found that endoplasmic reticulum (ER) stress responses driven by the IRE1α-XBP1 pathway not only promote cancer cell survival, but also provoke severe dendritic cell (DC) dysfunction in tumors. Targeting IRE1α-XBP1 represents a two-pronged approach to restrain malignant cells while eliciting concomitant antitumor immunity.
